Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Woodline Partners LP

Woodline Partners LP grew its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 156.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 854,309 shares of the company's stock after purchasing an additional 521,366 shares during the period. Woodline Partners LP owned approximately 1.25% of Replimune Group worth $10,346,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in REPL. Sterling Capital Management LLC increased its position in Replimune Group by 364.5% during the 4th quarter. Sterling Capital Management LLC now owns 2,109 shares of the company's stock valued at $26,000 after buying an additional 1,655 shares in the last quarter. Graham Capital Management L.P. increased its holdings in shares of Replimune Group by 6.1% during the fourth quarter. Graham Capital Management L.P. now owns 30,180 shares of the company's stock valued at $365,000 after acquiring an additional 1,731 shares in the last quarter. MetLife Investment Management LLC increased its holdings in shares of Replimune Group by 7.2% during the fourth quarter. MetLife Investment Management LLC now owns 37,659 shares of the company's stock valued at $456,000 after acquiring an additional 2,525 shares in the last quarter. Algert Global LLC raised its position in shares of Replimune Group by 7.1% in the 4th quarter. Algert Global LLC now owns 45,820 shares of the company's stock valued at $555,000 after purchasing an additional 3,057 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Replimune Group by 24.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 16,317 shares of the company's stock worth $198,000 after purchasing an additional 3,177 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. HC Wainwright upped their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, February 13th. JPMorgan Chase & Co. boosted their price objective on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Price Performance

Shares of NASDAQ:REPL opened at $8.76 on Friday. Replimune Group, Inc. has a twelve month low of $4.92 and a twelve month high of $17.00. The company has a current ratio of 11.43, a quick ratio of 11.43 and a debt-to-equity ratio of 0.14. The company has a market cap of $674.65 million, a PE ratio of -2.85 and a beta of 0.68. The company's 50 day moving average is $8.69 and its 200 day moving average is $11.24.

Replimune Group (NASDAQ:REPL - Get Free Report) last released its quarterly earnings data on Thursday, May 22nd. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.07). During the same quarter last year, the firm earned ($0.25) EPS. On average, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 EPS for the current year.

Insider Activity at Replimune Group

In related news, insider Konstantinos Xynos sold 7,952 shares of Replimune Group stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $8.06, for a total transaction of $64,093.12. Following the completion of the transaction, the insider now directly owns 146,933 shares in the company, valued at approximately $1,184,279.98. This trade represents a 5.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Andrew Schwendenman sold 3,287 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The shares were sold at an average price of $8.05, for a total value of $26,460.35. Following the completion of the transaction, the chief accounting officer now directly owns 68,284 shares of the company's stock, valued at $549,686.20. The trade was a 4.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 74,907 shares of company stock worth $603,655 over the last three months. Company insiders own 8.80% of the company's stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.

Want to see what other hedge funds are holding REPL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Replimune Group, Inc. (NASDAQ:REPL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.